InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Motif Bio is a clinical stage biopharmaceutical company developing novel antibioti...
Motif Bio is a clinical stage biopharmaceutical...
Systec & Solutions GmbH, with headquarters in Karlsruhe (Germany), is a specialize...
Systec & Solutions GmbH, with headquarters in K...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the ...
Moleculin Biotech, Inc. is a clinical stage pha...
Mereo BioPharma is a biopharmaceutical company focused on the development and comm...
Mereo BioPharma is a biopharmaceutical company ...
Diffusion Pharmaceuticals is a clinical stage company focused on improving the eff...
Diffusion Pharmaceuticals is a clinical stage c...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
TG Therapeutics is a biopharmaceutical company focused on the acquisition, develop...
TG Therapeutics is a biopharmaceutical company ...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Join the National Investor Network and get the latest information with your interests in mind.